Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac <scp>AL</scp> amyloidosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis

Published:2022-10 Issue:10 Volume:52 Page:1826-1830
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Brennan Xavier¹²^ORCID,Withers Barbara³,Jabbour Andrew¹²⁴,Milliken Sam²³,Kotlyar Eugene¹,Fay Keith³,Ma David³,Muthiah Kavitha¹²,Hamad Nada²³,Dodds Anthony³,Bart Nikki⁴,Keogh Anne¹⁴,Hayward Chris¹²⁴,Macdonald Peter¹²⁴,Moore John²³

Affiliation:

1. Cardiology Department St. Vincent's Hospital Sydney New South Wales Australia

2. University of New South Wales Sydney New South Wales Australia

3. Department of Haematology and Bone Marrow Transplant St. Vincent's Hospital Sydney New South Wales Australia

4. The Victor Chang Cardiac Research Institute Sydney New South Wales Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15926

Reference15 articles.

1. Systemic Cardiac Amyloidoses

2. Outcomes After Heart Transplantation for Amyloid Cardiomyopathy in the Modern Era

3. A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine

4. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

5. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of amyloidosis: present and future;European Heart Journal Supplements;2023-04-01

2. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy;Frontiers in Cardiovascular Medicine;2022-12-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3